z-logo
open-access-imgOpen Access
Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures
Author(s) -
Joo Sang Lee,
Lital N. Adler,
Hiren Karathia,
Narin Nard Carmel,
Shiran Rabinovich,
Noam Auslander,
Rom Keshet,
Noa Stettner,
Alon Silberman,
Lilach Agemy,
Daniel Helbling,
Raya Eilam,
Qin Sun,
Alexander Brandis,
Sergey Malitsky,
Maxim Itkin,
Hila Weiss,
Sivan Pinto,
Shelly Kalaora,
Ronen Levy,
Eilon Barnea,
Arie Admon,
David Dimmock,
Noam SternGinossar,
Avigdor Scherz,
Sandesh C.S. Nagamani,
Miguel Unda,
David M. Wilson,
Ronit Elhasid,
Arkaitz Carracedo,
Yardena Samuels,
Sridhar Hannenhalli,
Eytan Ruppin,
Ayelet Erez
Publication year - 2018
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2018.07.019
Subject(s) - biology , mutagenesis , urea cycle , carcinogenesis , transversion , pyrimidine metabolism , mutation , cancer research , enzyme , genetics , purine , biochemistry , microbiology and biotechnology , arginine , cancer , gene , amino acid
The urea cycle (UC) is the main pathway by which mammals dispose of waste nitrogen. We find that specific alterations in the expression of most UC enzymes occur in many tumors, leading to a general metabolic hallmark termed "UC dysregulation" (UCD). UCD elicits nitrogen diversion toward carbamoyl-phosphate synthetase2, aspartate transcarbamylase, and dihydrooratase (CAD) activation and enhances pyrimidine synthesis, resulting in detectable changes in nitrogen metabolites in both patient tumors and their bio-fluids. The accompanying excess of pyrimidine versus purine nucleotides results in a genomic signature consisting of transversion mutations at the DNA, RNA, and protein levels. This mutational bias is associated with increased numbers of hydrophobic tumor antigens and a better response to immune checkpoint inhibitors independent of mutational load. Taken together, our findings demonstrate that UCD is a common feature of tumors that profoundly affects carcinogenesis, mutagenesis, and immunotherapy response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom